Aldevron News
Transforming Genomic Medicine: A Historic Breakthrough
January 16, 2026 / by Aldevron
As published in Science News, the world witnessed a milestone in personalized medicine when the first CRISPR-based gene-editing therapy was administered to “Baby KJ” Muldoon in may of 2025. This life-saving treatment for Urea Cycle Disorder (UCD) was developed in just six months. This was an achievement made possible through unprecedented collaboration between academic researchers and industry leaders.
Aldevron, together with Integrated DNA Technologies (IDT) and Acuitas Therapeutics, accelerated the development of this complex therapy by leveraging advanced mRNA and gRNA manufacturing platforms, clinically validated lipid nanoparticle (LNP) technology, and a unified regulatory approach. The result: a first-of-its-kind treatment that redefines what’s possible in genomic medicine.
This breakthrough is more than a success story. It’s a blueprint for the future. By streamlining CRISPR workflows and aligning quality systems, Aldevron and our partners at IDT and Acuitas Therapeutics are paving the way for rapid, personalized therapies that transform lives.
Learn how we are powering innovation for genomic medicine pioneers.